Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06373497 · ClinicalTrials.gov registry record · Early Phase 1
Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography
A Early Phase 1 study of Oligometastatic Disease, sponsored by Katelyn Atkins.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06373497 is a Early Phase 1 study of Oligometastatic Disease that is actively recruiting participants, run by Katelyn Atkins. The registered enrollment target is 10 participants, below the 62-participant average among 4 other Oligometastatic Disease trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06373497, a Early Phase 1 study of Oligometastatic Disease, is actively recruiting participants, sponsored by Katelyn Atkins.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The prospective single-arm pilot study, ATHERO-RT: Real-Time Atherosclerosis Activity after Thoracic Radiotherapy using Sodium Fluoride Positron Emission Tomography, will aim to: 1. To deploy first-in-kind application of fluorine 18-sodium fluoride (18F-NaF) PET (Positron Emission Tomography) /MRI (Magnetic Resonance Imaging) imaging to detect real-time atherosclerosis activity at the time of cancer diagnosis and after cardiac radiation exposure 2. To detect longitudinal changes in clonal hematopoiesis (CH) genetic architecture following thoracic RT (Radiation Therapy) in patients at high risk of cardiac dysfunction, and 3. To measure perturbations in the immune-modulatory and metabolic states following thoracic RT (Radiation Therapy) exposure in patients at high risk of cardiac dysfunction. Eligible patients will be adults (≥18 years old) with Stage II-III or oligo-metastatic stage IV malignancy (any histology) at high risk for RT-associated cardiac toxicity (defined as receiving ≥30 Gy (Gray) RT where the heart is in the treatment field54). The study will enroll a total of 10 subjects, recruited from Cedars-Sinai Medical Center. The primary endpoint will be successful completion of 18F-NaF PET imaging at the baseline and 6-month post-RT time points. Blood will be collected at baseline, end of RT, and 6-months post-RT.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18-F-NaF Cardiac PET/MRI and
- DIAGNOSTIC_TEST CT Angiogram
Study Locations (1)
California
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2026-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06373497
The ClinicalTrials.gov registry entry for NCT06373497 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 4 other Oligometastatic Disease trials with a reported enrollment target (84% lower). The listed sponsor is Katelyn Atkins, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oligometastatic Disease appearing as the primary indexed condition, and to 2 interventions - of which 18-F-NaF Cardiac PET/MRI and is the first listed.
NCT06373497 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06373497 about?
NCT06373497 is a clinical study titled "Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography". The prospective single-arm pilot study, ATHERO-RT: Real-Time Atherosclerosis Activity after Thoracic Radiotherapy using Sodium Fluoride Positron Emission Tomography, will aim to: 1. To deploy first-in-kind application of fluorine 18-sodium fluoride (18F-NaF) PET (Positron Emission Tomography) /MRI ...
What is the current status of trial NCT06373497?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-06-19. Estimated completion is 2026-10.
What conditions does trial NCT06373497 study?
This clinical trial studies the following conditions: Oligometastatic Disease.
What interventions are being tested in trial NCT06373497?
The interventions under investigation include: 18-F-NaF Cardiac PET/MRI and (DIAGNOSTIC_TEST), CT Angiogram (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06373497?
This trial is sponsored by Katelyn Atkins, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06373497 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oligometastatic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TERPS Trial for de Novo Oligometastic Prostate Cancer
RECRUITING · Phase 2
-
Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)
RECRUITING · Phase 1
-
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
RECRUITING · Phase 2
-
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.